|
| Press Releases |
|
 |
|
| Tuesday, March 4, 2025 |
|
|
Micreos Pharmaceuticals 與生物製劑 CDMO Northway Biotech 合作推動其工程化內溶素療法製造計畫 |
| more info >> |
|
|
Micreos Pharmaceuticals Partners With Biologics CDMO Northway Biotech for Its Engineered Endolysin Therapeutic Manufacturing Program |
| Micreos Pharmaceuticals AG ("Micreos"), a preclinical-stage biopharmaceutical company, specializing in developing Engineered Endolysin therapies to target harmful pathogens that cause disease aggravation, has entered into a strategic partnership with Northway Biotech ("NBT"), a Contract Development and Manufacturing Organization (CDMO) to develop scalable cGMP production processes for Micreos' biologic therapeutic MEndoB, which is the first-in-class dual-active domain targeted medicine that will enter the clinic in the coming months as an investigational therapeutic to treat Atopic Dermatitis. more info >> |
|
| Wednesday, February 5, 2025 |
|
|
Mallia Therapeutics 與 Northway Biotech 宣布合作生產可溶性 CD83 蛋白 用於脫髮治療 |
| Mallia Therapeutics（「Mallia」）是一家致力於開發新型脫髮治療方案的生物製藥公司，Northway Biotech（「NBT」）則是一家專業從事生物製劑的合同開發與製造組織（CDMO）。雙方宣布建立合作夥伴關係，共同開發 Mallia 的可溶性 CD83 蛋白（sCD83）生產工藝，並負責其製造，該治療方案旨在促進毛囊形成與生長。 more info >> |
|
| Tuesday, February 4, 2025 |
|
|
Mallia Therapeutics and Northway Biotech Announce Partnership for the Manufacturing of Soluble CD83 Protein for Hair Loss Treatment |
| Mallia Therapeutics ("Mallia"), a biopharmaceutical company developing novel treatments for hair loss, and Northway Biotech ("NBT"), a biologics Contract Development and Manufacturing Organization (CDMO), have announced a partnership for the development of the production process and manufacturing of Mallia's soluble CD83 protein (sCD83), a treatment aimed at promoting hair follicle formation and growth. more info >> |
|
| Tuesday, August 1, 2023 |
|
|
iTolerance, Inc. and Northway Biotech Announce Partnership Agreement for Manufacturing of Streptavidin-FasL Fusion Protein for Innovative iTOL-100 Immunomodulatory Technology |
| iTOL-100 technology has broad applicability and can be applied to both allogenic and stem cell-derived organoids across a number of diseases. Manufacturing agreement supports advancement of iTolerance's development of iTOL-100 towards first in human clinical study for lead program, iTOL-102. more info >> |
|
|
iTolerance, Inc. and Northway Biotech Announce Partnership Agreement for Manufacturing of Streptavidin-FasL Fusion Protein for Innovative iTOL-100 Immunomodulatory Technology |
| iTOL-100 technology has broad applicability and can be applied to both allogenic and stem cell-derived organoids across a number of diseases. Manufacturing agreement supports advancement of iTolerance's development of iTOL-100 towards first in human clinical study for lead program, iTOL-102. more info >> |
|
| Thursday, May 25, 2023 |
|
|
Northway Biotech Set to Launch Advanced Microbial and Mammalian GMP Facilities in Massachusetts |
| Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), established in 2004, with an EMA and FDA-compliant, state-of-the-art cGMP manufacturing site in Vilnius, Lithuania, announced the completion of its expansion project for cGMP manufacturing facilities in Waltham, Massachusetts. This significant accomplishment further solidifies Northway Biotech's standing as an influential player in the global biopharmaceutical landscape. more info >> |
|
| Wednesday, May 17, 2023 |
|
|
tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat |
| tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
SinoMab BioScience Limited Breakthrough Phase 1b POC Results for SM17 in Atopic Dermatitis
Apr 10, 2025 22:35 JST
|
|
|
The 3rd InnoEX spotlights five key technology areas Exploring developments in low-altitude economy, AI, robotics and more
Apr 10, 2025 21:30 HKT/SGT
|
|
|
中國抗體製藥有限公司SM17治療特應性皮炎1b期概念驗證臨床試驗取得突破性結果
Apr 10, 2025 21:20 HKT/SGT
|
|
|
Sunshine Insurance: Practicing 'Insurance for the People'
Apr 10, 2025 21:03 HKT/SGT
|
|
|
Seven HKTDC mega events showcase Asia's creative hub
Apr 10, 2025 19:25 HKT/SGT
|
|
|
U.S. Polo Assn. 慶祝推出全球獲獎數位雜誌《Field X Fashion》第2期，融合運動與時尚的品牌盛典
Apr 10, 2025 19:00 HKT/SGT
|
|
|
U.S. Polo Assn. Celebrates Launch of Field X Fashion, Issue 2, Brand's Award-Winning Global, Digital Magazine Celebrating Sport and Fashion
Apr 10, 2025 19:00 HKT/SGT
|
|
|
Hola Prime Expands into On-Exchange Cryptos, Bringing Centralized Exchange Access to Crypto Traders
Apr 10, 2025 16:00: JST
|
|
|
Mitsubishi Logisnext Delivers Container Terminal Gate System with Enhanced Functionality to Port of Osaka
Apr 10, 2025 16:23 JST
|
|
|
Hola Prime Expands into On-Exchange Cryptos, Bringing Centralized Exchange Access to Crypto Traders
Apr 10, 2025 15:00 HKT/SGT
|
|
|
Mitsubishi Shipbuilding Acquired Approval in Principle (AiP) from Classification Society for the Basic Design of an Onboard Carbon Capture and Storage System
Apr 10, 2025 14:17 JST
|
|
|
Hebe Biotechnology Appoints Industry Insider Dr. Hannes Hentze as Chief Development Officer to Advance Next-Generation GLP-1 RA Weight Loss Therapy
Apr 10, 2025 12:57 HKT/SGT
|
|
|
Honda NC750X Named Winner in 2025 Red Dot Design Award: Product Design Category, EM1 e: Wins 2025 iF Design Award: Product Design Category
Apr 10, 2025 13:13 JST
|
|
|
Transform Your Social Media Profile into a Sales Catalog with GoDaddy's Show in Bio Tool
Apr 10, 2025 08:00 HKT/SGT
|
|
|
analytica Vietnam 2025 Opens Tomorrow: The Leading Laboratory Exhibition Returns to Vietnam
Apr 9, 2025 22:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
